H.C. Wainwright Reiterates Buy on Omeros After AstraZeneca’s Ultomiris Phase 3 Miss
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
NOTRELOAD AI
Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
Piper Sandler Upgrades Rivian to Overweight on Smooth R2 Launch and Stronger Demand
Piper Sandler upgrades Rivian to Overweight with a $20 target, citing smooth R2 launch, stronger demand, and a de-risked balance sheet.
Circle Secures Massive Blockchain Patent Portfolio from IBM to Supercharge USDC and Arc
Circle buys nearly 1,000 blockchain patents from IBM, becoming the top U.S. holder.
Wolfe Research Warns: Corcept Stock Pricing in Too Many Perfect Outcomes
Corcept stock looks overpriced despite strong drug sales; analysts warn expectations are too high and risks could drag shares lower.
Jefferies Turns Bullish on Detroit: Upgrades Ford and General Motors
Jefferies upgrades Ford to Buy ($17.50 PT) and GM to Buy ($99 PT). Stronger production, healthy U.S. demand and solid 2027 outlook drive the dual upgrades.